Active substance
Oxytetracycline
- SFDA 4
- US FDA 9
- NHS prices 1
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| IMPERACINE 250MG TAB | 250 mg | Tablet · Oral use | 16 Blister | SAR 8.05 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| OXYTETRACYCLINE OINT 3% | 3 % | Ointment · Topical | 1 Tube | SAR 4.00 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| TERRAMYCIN EYE OINT 1% | 0.1 % | Eye ointment · Ocular use | 1 Tube | SAR 3.75 | NCE · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| TERRAMYCIN TOPICAL OINT | 3 % | Ointment · Topical | 1 Tube | SAR 6.60 | NCE · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| OXYTETRACYCLINE HYDROCHLORIDE | EQ 250MG BASE | capsule · oral | PROTER | Discontinued | 29 Jan 1964 |
| TERRAMYCIN | EQ 125MG BASE; EQ 250MG BASE | capsule · oral | PFIZER | Discontinued | 8 Sep 1964 |
| OXYTETRACYCLINE HYDROCHLORIDE | EQ 250MG BASE | capsule · oral | IMPAX LABS | Discontinued | 9 Aug 1967 |
| OXY-KESSO-TETRA | EQ 250MG BASE | capsule · oral | FERRANTE | Discontinued | 11 Aug 1967 |
| OXYTETRACYCLINE HYDROCHLORIDE | EQ 250MG BASE | capsule · oral | HIKMA | Discontinued | 29 Sep 1967 |
| TERRAMYCIN | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL | injectable · injection | PFIZER | Discontinued | |
| TERRAMYCIN | EQ 125MG BASE/5ML | syrup · oral | PFIZER | Discontinued | |
| OXYTETRACYCLINE HYDROCHLORIDE | EQ 250MG BASE | capsule · oral | PUREPAC PHARM | Discontinued | |
| TERRAMYCIN | 250MG | tablet · oral | PFIZER | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Oxytetracycline 250mg tablets | £49.99 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 21.1. Ophthalmological preparations > Anti-infective agents · core
Therapeutic equivalent to tetracycline for Other specified conjunctivitis; Therapeutic equivalent to tetracycline for Infectious keratitis; Therapeutic equivalent to tetracycline for Infectious blepharitis; Therapeutic equivalent to tetracycline for Trachoma
Combinations containing Oxytetracycline
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.